Boston Scientific (BSX)
103.52
-0.33 (-0.32%)
NYSE · Last Trade: Oct 23rd, 2:06 PM EDT
Via Benzinga · October 23, 2025
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · October 22, 2025
Shares of medical device company Boston Scientific (NYSE:BSX)
jumped 4.4% in the morning session after the company reported strong third-quarter results that topped Wall Street's forecasts and raised its full-year financial outlook.
Via StockStory · October 22, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · October 22, 2025
Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533Mstocktwits.com
Via Stocktwits · October 17, 2025
Risk sentiment deteriorated sharply on Wednesday as a wave of disappointing earnings guidance and escalating U.S.-China trade tensions rattled investor confidence.
Via Benzinga · October 22, 2025
Goldman Sachs analyst David Roman reiterated a Buy rating and $120 price target for Boston Scientific after strong Q3 results and raised guidance.
Via Benzinga · October 22, 2025
Boston Scientific (NYSE: BSX) has delivered an exceptional third-quarter 2025 earnings report, significantly surpassing analyst expectations and reinforcing its position as a leading innovator in the medical device industry. The strong performance, highlighted by robust sales growth and an upward revision of full-year guidance, has sent a positive signal to
Via MarketMinute · October 22, 2025
Boston Scientific Q3 revenue hit $5.07 billion, beating forecasts. The company raised its full-year guidance based on strong segment growth.
Via Benzinga · October 22, 2025
Boston Scientific stock jumped early Wednesday on a strong 2025 outlook following its third-quarter sales and earnings beat.
Via Investor's Business Daily · October 22, 2025
The Death Cross is something you never want to see on a stock you own. Take caution with these three companies that recently were visited by this scary signal.
Via MarketBeat · October 22, 2025
Medical device company Boston Scientific (NYSE:BSX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was better than expected at $5.27 billion at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 5.1% above analysts’ consensus estimates.
Via StockStory · October 22, 2025
Boston Scientific beats Q3 2025 earnings and revenue forecasts, reporting strong sales growth and issuing optimistic Q4 guidance.
Via Chartmill · October 22, 2025
Medical device company Boston Scientific (NYSE:BSX)
will be announcing earnings results this Wednesday morning. Here’s what to expect.
Via StockStory · October 20, 2025
Via Benzinga · October 17, 2025
Boston Scientific Corp (NYSE: BSX) to acquire Nalu Medical Inc. for $600 million in cash. Deal expected to close in first half of 2026.
Via Benzinga · October 17, 2025
Via Benzinga · October 15, 2025
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Via StockStory · October 14, 2025
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · October 8, 2025
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via StockStory · October 6, 2025
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Via MarketMinute · October 2, 2025